Last reviewed · How we verify
Angiotensin II Injection
Angiotensin II is a vasoactive peptide that binds to angiotensin II receptors to increase blood pressure and restore vascular tone in patients with hypotension.
Angiotensin II is a vasoactive peptide that binds to angiotensin II receptors to increase blood pressure and restore vascular tone in patients with hypotension. Used for Distributive shock (septic shock) with hypotension refractory to catecholamines, Severe hypotension in critically ill patients.
At a glance
| Generic name | Angiotensin II Injection |
|---|---|
| Sponsor | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
| Drug class | Vasoconstrictor; Angiotensin II receptor agonist |
| Target | Angiotensin II Type 1 (AT1) receptor; Angiotensin II Type 2 (AT2) receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular; Critical Care |
| Phase | Phase 3 |
Mechanism of action
Angiotensin II acts as a potent vasoconstrictor by binding to AT1 and AT2 receptors on vascular smooth muscle and endothelial cells, leading to increased peripheral vascular resistance and blood pressure elevation. It also promotes aldosterone release and sodium retention, further contributing to hemodynamic stabilization. This mechanism is particularly useful in treating distributive shock and severe hypotension where catecholamine-resistant hypotension occurs.
Approved indications
- Distributive shock (septic shock) with hypotension refractory to catecholamines
- Severe hypotension in critically ill patients
Common side effects
- Hypertension
- Thrombotic events
- Arrhythmias
- Ischemic events
Key clinical trials
- Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) (PHASE2)
- Radioembolization With Intra-arterial Angiotensin II to Improve Tumor-absorbed Dose (RADIANT) (PHASE2)
- A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (PHASE2)
- Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (PHASE2)
- : Vascular Function in Health and Disease (PHASE1)
- A Study to Evaluate Zilebesiran in Japanese Patients With Mild to Moderate Hypertension (PHASE1, PHASE2)
- Safety and Efficacy of Angiotensin (1-7) in Persons With Moderate to Severe Traumatic Brain Injury (PHASE1, PHASE2)
- A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx in Hypertensive Participants With Uncontrolled Blood Pressure (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Angiotensin II Injection CI brief — competitive landscape report
- Angiotensin II Injection updates RSS · CI watch RSS
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. portfolio CI